Merck Dumps Sirna RNAi Assets for $175M


Jan 14, 2014

Merck has agreed to sell its Sirna Therapeutics assets to Alnylam Pharmaceuticals, a RNAi therapeutics company, for an upfront payment of $175 million in cash and equity.

The price tag is significantly less than the $1.1B Merck paid to acquire the promising biotechnology firm back in 2006, when RNAi-based therapies were peaking in the industry.

With this sale, Merck has almost completely eliminated RNAi efforts from its portfolio.

Read the press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments